Simulations Plus, Inc. (SLP)

NMS – Real vaqt narxi. Valyuta: USD

13.96

-0.73 (-4.97%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push

Simulations Plus, Inc. (NASDAQ:SLP) shares are trading lower on Wednesday as the company announced a collaboration with NVIDIA Corp (NASDAQ:NVDA), aimed at enhancing GPU-accelerated simulation and AI-assisted workflows in drug development.

06.05.2026

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle. The collaboration brings together Simu.

28.04.2026

Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised

CDNS tops Q1 estimates, launches agentic AI Super Agents, hits a record $8B backlog, and raises its 2026 revenue outlook.

21.04.2026

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (“Lonza”), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a me.

20.04.2026

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry's future workforce. More than 1,400 scientists.

15.04.2026

Simulations Plus: Better Quarter, Same Doubts

Simulations Plus, Inc. remains a Hold as business improvement is insufficient to warrant a Buy, despite stabilization post-earnings. Q2 2026 revenue grew 8% YoY to $24.3M, with strong software renewals (91%) and expanding services backlog (+18% YoY). SLP trades at ~14x blended earnings, appearing cheap versus history but still expensive on GAAP metrics given slow revenue and cash flow growth.

12.04.2026

Simulations Plus: Down Substantially, Not An Automatic Buy

Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

21.04.2026

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (“Lonza”), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a me.

20.04.2026

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the successful completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development (MIDD) and strengthen the scientific foundation of the industry's future workforce. More than 1,400 scientists.

09.04.2026

Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its second quarter fiscal 2026, ended February 28, 2026. Second Quarter 2026 Financial Highlights (as compared to second quarter 2025) Total revenue increased 8% to $24.3 million Software revenue increased 9% to $14.6 million, repres.

Simulations Plus, Inc. (SLP)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Simulations Plus, Inc. (SLP)

Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Simulations Plus: Better Quarter, Same Doubts

Simulations Plus: Down Substantially, Not An Automatic Buy

Videolar

No Data

Press-relizlar

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results

Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Simulations Plus: Better Quarter, Same Doubts

Simulations Plus: Down Substantially, Not An Automatic Buy

Videolar

No Data

Press-relizlar

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results

Search stocks

Simulations Plus, Inc. (SLP)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Simulations Plus, Inc. (SLP)

Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Simulations Plus: Better Quarter, Same Doubts

Simulations Plus: Down Substantially, Not An Automatic Buy

Videolar

No Data

Press-relizlar

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results

Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Simulations Plus: Better Quarter, Same Doubts

Simulations Plus: Down Substantially, Not An Automatic Buy

Videolar

No Data

Press-relizlar

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results